Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study

Trapp E, Steidl J, Rack B, Kupka MS, Andergassen U, Jueckstock J, Kurt A, Vilsmaier T, De Gregorio A, De Gregorio N, Tzschaschel M, Lato C, Polasik A, Tesch H, Schneeweiss A, Beckmann M, Fasching P, Janni W, Mueller V (2017)

Publication Type: Journal article

Publication year: 2017

Journal

BREAST Elsevier

Book Volume: 35

Pages Range: 130-135

DOI: 10.1016/j.breast.2017.07.007

Abstract

BACKGROUND: Premenopausal women undergoing chemotherapy are at high risk for premature ovarian failure and its long-term consequences. Data on potential markers to evaluate ovarian reserve pre- and posttreatment are limited. Anti-Müllerian hormone (AMH) known for ovarian reserve in reproductive medicine could be a surrogate marker and was assessed in premenopausal breast cancer patients of the SUCCESS A study (EUDRA-CT no. 2005-000490-21). METHODS: We identified 170 premenopausal patients, age ≤ 40 years at trial entry, who received FEC-Doc as taxane-anthracylince based chemotherapy. Blood samples were taken at three time points: Before, four weeks after and two years after adjuvant chemotherapy. Serum AMH-levels were evaluated in a central laboratory by a quantitative immunoassay AMH Gen II ELISA (Beckman Coulter, Brea, USA). RESULTS: Median age was 36 years (21-40 years). Median serum AMH-level before chemotherapy was 1.37 ng/ml (range < 0.1-11.3 ng/ml). Four weeks after chemotherapy AMH-levels dropped in 98.6% of the patients to <0.1 ng/ml (range < 0.1-0.21 ng/ml). After two years, 73.3% (n = 101) showed no evidence of ovarian function recovery (AMH <0.1 ng/ml, range < 0.1-3.9 ng/ml). Permanent chemotherapy induced amenorrhea occurred only in 50.6% of the patients. CONCLUSIONS: In this analysis, premenopausal patients showed a high rate of ovarian impairment reflected by low AMH-levels after chemotherapy.

Authors with CRIS profile

Matthias Beckmann Lehrstuhl für Geburtshilfe und Frauenheilkunde Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Universitätsklinikum Ulm DE Germany (DE) Ludwig-Maximilians-Universität (LMU) DE Germany (DE) Centrum für Hämatologie und Onkologie Bethanien DE Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) Universitätsklinikum Heidelberg DE Germany (DE)

How to cite

APA:

Trapp, E., Steidl, J., Rack, B., Kupka, M.S., Andergassen, U., Jueckstock, J.,... Mueller, V. (2017). Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study. BREAST , 35, 130-135. https://doi.org/10.1016/j.breast.2017.07.007

MLA:

Trapp, Elisabeth, et al. "Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study." BREAST 35 (2017): 130-135.

BibTeX: Download